GE HealthCare reports third quarter 2026 financial results
Business Wire•28/10/2026•06:20 ET
1
Key Highlights
- ➤Revenue $5.5 billion, up 7.2%; organic revenue growth reached 6.2%
- ➤Diluted EPS $1.36, up 39.1%; adjusted EPS grew 25.1% to $1.34
- ➤2026 organic revenue growth guidance raised to approximately 4.0%
- ➤SOFIE Biosciences acquisition priced at $945 million cash, closing expected first-half 2027
- ➤Backlog reached $23.7 billion, with 1.03-times book-to-bill ratio
Expert Statements
Peter Arduini, President and CEO of GE HealthCare
“We delivered strong top-line growth and margin expansion across all segments, and robust EPS growth in the third quarter. This reflects our teams’ commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations. With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.”
* Delivers top- and bottom-line growth ahead of Company expectations and raises full-year 2026 guidance
* Organic orders growth of 4.0%, book-to-bill of 1.03 times and backlog of $23.7 billion
Get started
Create a free account to read the full story.